urate oxidase [KO:K00365] [EC:1.7.3.3]
Rasburicase is contraindicated in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency [DS:H00668] because this can precipitate hemolytic anemia.
Treatment of malignancy-associated or chemotherapy-induced hyperuricemia
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
V VARIOUS
V03 ALL OTHER THERAPEUTIC PRODUCTS
V03A ALL OTHER THERAPEUTIC PRODUCTS
V03AF Detoxifying agents for antineoplastic treatment
V03AF07 Rasburicase
D05704 Rasburicase (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Antineoplastic Adjuncts/Mitigators
Rasburicase
D05704 Rasburicase (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
395 Enzyme preparations
3959 Others
D05704 Rasburicase (USAN/INN); Rasburicase (genetical recombination) (JAN)
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D05704
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D05704
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D05704
